Scientists behind Big Pharma drugs gonged
Five scientists and a Canadian-American actor behind big name drug discoveries have been recognised for their efforts at the 2026 Lasker Foundation Awards
Five scientists and a Canadian-American actor behind big name drug discoveries have been recognised for their efforts at the 2026 Lasker Foundation Awards
Millions in funding will allow up to 200 people to access a drug currently in a Phase 2/3 trial, providing real-world clinical data from a broader population.
After 11 years working for the same Big Pharma and almost four serving on the Board of the industry body, this executive is the latest leadership departure
Nineteen days before the turn of the calendar, the Govt has announced the PBS listing of a new treatment for patients with a debilitating disease
Medical affairs heavyweights joined a panel at MAPA to outline how people can take the lead in their organisations whatever the title they have
TGA grants licence to manufacture therapeutic goods, marking a significant milestone for the company and sovereign capability for Australia
Relocating to Australia from London, this global value and access high-flyer has been snapped up by J&J for a senior leadership position
Pharma sets an ambitious goal to establish a portfolio of more than 100 biosimilars by 2040, up substantially from the 13 it currently markets
The Health Minister is “very confident” that other immunotherapy drug makers will submit broad PBS listing submissions following in the footsteps of a drug he referred to as the 'Beast' which has just won multi-cancer reimbursement
After 12 years, this well-known leader who has worked tirelessly for equity in cancer care is standing down with a successor already named
Attendees given insights into the way AI will change their roles and told how important it is that they exert influence independent of their job title
A living, curated repository bringing the growing evidence base around the medical affairs function together in one place - and its free
Company sponsorship of the Poweroos reflects a broader commitment to supporting people living with rare and neuromuscular conditions
An industry-wide upheaval is coming to pharma with a monster patent cliff fall to hit in the next four years and even one of the world's newest blockbusters is not safe
Thirteen medical affairs professionals, some representing their teams, have been recognised for their outstanding contribution to the industry across Australia and New Zealand
When it comes to favourite pharmas, one company is a clear standout according to this patient cohort which says industry's overall corporate reputation has improved... except in one crucial area
Australian States and Territories have been ranked on how well they support families who are getting treatment for cancer, and only one passed muster.
Minister deftly sidesteps questions about growing speculation he is the Labor Party's "leader-in-waiting" when Anthony Albanese's time as PM comes to an end
Rare Cancers Australia is calling for a raft of reforms, including reducing the median time from TGA approval of a medicine to PBS listing from 639 days to just 60
The agenda for the November PBAC meeting has been updated with one company rejected in July making quick work of trying again
A new asthma treatment set to be considered for PBS funding at the PBAC's intracycle meeting this month has been approved for use in Australia
Two senior pharma executives - one a former Aussie GM - have called out perfect work-life balance as an unrealistic expectation placed on the industry
Jobs go following a recent field force review with changes made to ensure the company's customer coverage model reflects an evolving market
High-flyer has been promoted to Country Lead, taking responsibility for heading the company's innovative medicines business in Australia
The BMS Patient & Parliament Summit in Canberra has called for urgent action for patients who fear they won't survive the wait for treatment
A survey including Australian doctors has revealed which HCPs have the highest trust in AI tools - and which specialties are not AI fans